GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (STU:1ZLB) » Definitions » Valuation Rank

Zai Lab (STU:1ZLB) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Zai Lab Valuation Rank Related Terms

Thank you for viewing the detailed overview of Zai Lab's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Zai Lab Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (STU:1ZLB) » Definitions » Valuation Rank
Comparable Companies
PTCT RNA ADMA ACLX IONS SWTX RARE CYTK RYTM AKRO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ZLAB:USA ZLAB N:Mexico 09688:Hong Kong 1ZLB:Germany 1ZL:Germany 1ZL:Germany
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Website
https://www.zailaboratory.com
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.